A Convenient Method for Measuring Blood Ascorbate Concentrations in Patients Receiving High-Dose Intravenous Ascorbate

Ma, Yan; Sullivan, Garrett G; Schrick, Elizabeth; Choi, In‐Young; He, Zhuoya; Lierman, JoAnn; Lee, Phil; Drisko, Jeanne; Chen, Qi

doi:10.1080/07315724.2013.791167

Cited by 14 publications

(16 citation statements)

References 15 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is noted that care must be taken in patients with diabetes because AA can falsely elevate glucometer readings substantially (ie, values can range greater than 400 mg/dL). 35 Pharmacokinetic studies have generally observed an elimination half-life of approximately 2 hours, 15 , 36 with the implication that glucometer readings could remain abnormal for 6 to 8 hours postinfusion. Thus, it is important to remind patients with diabetes to be cautious with regard to treating themselves with added insulin if readings remain elevated after receiving IV AA.…”

Section: Discussionmentioning

confidence: 99%

Retrospective Evaluation of Clinical Experience With Intravenous Ascorbic Acid in Patients With Cancer

et al. 2018

View full text Add to dashboard Cite

Background. Intravenous ascorbic acid (IV AA) has been used extensively in cancer patients throughout the United States. Currently, there are limited data on the safety and clinical effects of IV AA. The purpose of this study was to expand the current literature using a retrospective analysis of adverse events and symptomatic changes of IV AA in a large sample of cancer patients. Methods. We conducted a retrospective chart review of all patients receiving IV AA for cancer at the Thomas Jefferson University Hospital over a 7-year period. We assessed all reports of adverse events, laboratory findings, and hospital or emergency department admissions. We also reviewed quality-of-life data, including fatigue, nausea, pain, appetite, and mood. Results. There were 86 patients who received a total of 3034 doses of IV AA ranging from 50 to 150g. In all, 32 patients received only ascorbic acid as part of their cancer management (1197 doses), whereas 54 patients received ascorbic acid in conjunction with chemotherapy (1837 doses). The most common adverse events related to ascorbic acid were temporary nausea and discomfort at the injection site. All events reported in the ascorbic acid alone group were associated with less than 3% of the total number of infusions. Patients, overall, reported improvements in fatigue, pain, and mood while receiving ascorbic acid. Conclusions. The results of this retrospective analysis support the growing evidence that IV AA is generally safe and well tolerated in patients with cancer, and may be useful in symptom management and improving quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective Evaluation of Clinical Experience With Intravenous Ascorbic Acid in Patients With Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Finally, it should be noted that high plasma vitamin C concentrations interfere with most skin-prick or blood glucose measurements by generating either a falsely high or falsely low result [ 49 , 50 ]. For this reason, it is important not to measure (or if inadvertently measured, discount) the blood glucose concentration indicated by such tests until 12 hours after an IVC infusion has ended.…”

Section: Discussionmentioning

confidence: 99%

High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial

et al. 2015

View full text Add to dashboard Cite

BackgroundBiological and some clinical evidence suggest that high-dose intravenous vitamin C (IVC) could increase the effectiveness of cancer chemotherapy. IVC is widely used by integrative and complementary cancer therapists, but rigorous data are lacking as to its safety and which cancers and chemotherapy regimens would be the most promising to investigate in detail.Methods and FindingsWe carried out a phase I-II safety, tolerability, pharmacokinetic and efficacy trial of IVC combined with chemotherapy in patients whose treating oncologist judged that standard-of-care or off-label chemotherapy offered less than a 33% likelihood of a meaningful response. We documented adverse events and toxicity associated with IVC infusions, determined pre- and post-chemotherapy vitamin C and oxalic acid pharmacokinetic profiles, and monitored objective clinical responses, mood and quality of life. Fourteen patients were enrolled. IVC was safe and generally well tolerated, although some patients experienced transient adverse events during or after IVC infusions. The pre- and post-chemotherapy pharmacokinetic profiles suggested that tissue uptake of vitamin C increases after chemotherapy, with no increase in urinary oxalic acid excretion. Three patients with different types of cancer experienced unexpected transient stable disease, increased energy and functional improvement.ConclusionsDespite IVC’s biological and clinical plausibility, career cancer investigators currently ignore it while integrative cancer therapists use it widely but without reporting the kind of clinical data that is normally gathered in cancer drug development. The present study neither proves nor disproves IVC’s value in cancer therapy, but it provides practical information, and indicates a feasible way to evaluate this plausible but unproven therapy in an academic environment that is currently uninterested in it. If carried out in sufficient numbers, simple studies like this one could identify specific clusters of cancer type, chemotherapy regimen and IVC in which exceptional responses occur frequently enough to justify appropriately focused clinical trials.Trial RegistrationClinicalTrials.gov NCT01050621

show abstract

“…Cara alternatif untuk mengukur kadar vitamin C serum masih sedang dipelajari, salah satunya adalah mengukur kadar vitamin C dalam glukosa darah. 29 Pemeriksaan koagulasi juga dapat dilakukan untuk menyingkirkan kemungkinan gangguan perdarahan. Pemeriksaan sederhana PT/APTT (yang biasanya lebih mudah dilakukan dibanding von Willebrand Factor/ vWF) dapat dilakukan untuk menyingkirkan diagnosis selain penyakit skorbut.…”

Section: Pemeriksaan Penunjang Skorbut Pada Thalassemiaunclassified

Vitamin C Dosis Rendah untuk Skorbut pada Thalassemia

Wahidiyat¹,

Yosia²

2019

View full text Add to dashboard Cite

Belakangan ini beberapa pasien thalassemia mengeluhkan gusi berdarah, purpura dan nyeri disertai bengkak pada sendi. Kondisi berikut merupakan kondisi yang sangat serupa dengan tanda-tanda skorbut (kekurangan vitamin C). Sampai saat ini belum ada panduan pemberian vitamin C yang aman bagi pasien thalassemia (mengingat vitamin C dapat meningkatkan besi labil yang berbahaya pada pasien thalassemia). Tinjauan pustaka ini bertujuan untuk membahas informasi mengenai skorbut pada thalassemia disertai observasi manifestasi skorbut pada pasien thalassemia di seluruh dunia. Selain itu juga akan melihat kemungkinan pemberian suplemen vitamin C dosis rendah yang aman untuk mengatasi skorbut. Lima laporan kasus dengan total 7 kasus skorbut pada pasien thalassemia diikutkan dalam laporan ini[nc1] . Laporan kasus yang ditemukan berasal dari Sri Lanka, Kanada, Amerika Serikat dan India. Suplementasi vitamin C diberikan kepada semua kasus dengan dosis berkisar antara 50 mg/hari sampai 500 mg/hari. Semua keluhan hilang setelah pemberian vitamin C. Manifestasi klinis skorbut pada pasien thalassemia adalah gingivitis, perdarahan mukosa, nyeri dan kelemahan sendi dan purpura. Terapi [nc2] vitamin C dengan dosis rendah 50 mg/hari dapat menghilangkan keluhan klinis skorbut pada pasien thalassemia.

show abstract

A Convenient Method for Measuring Blood Ascorbate Concentrations in Patients Receiving High-Dose Intravenous Ascorbate

Cited by 14 publications

References 15 publications

Retrospective Evaluation of Clinical Experience With Intravenous Ascorbic Acid in Patients With Cancer

Retrospective Evaluation of Clinical Experience With Intravenous Ascorbic Acid in Patients With Cancer

High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial

Vitamin C Dosis Rendah untuk Skorbut pada Thalassemia

Contact Info

Product

Resources

About